Streetbeat News

Stock Prices

GOOGL

Alphabet is considered significantly undervalued with strong Q3 results and a robust balance sheet. The potential return of the Trump Administration is expected to ease antitrust pressures, creating a favorable environment for Alphabet's growth and innovation.

Portfolio Pulse from

November 11, 2024 | 2:15 pm

DAC

Danaos is expected to report its Q3 earnings, with anticipated negative impacts due to ongoing market disruptions.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

AAAU

Gold and silver prices are under pressure due to a strong U.S. dollar and concerns about demand. This situation is affecting commodities markets, with potential implications for related financial instruments.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

ABBV

AbbVie's experimental schizophrenia drug did not meet the primary objectives in two mid-stage trials, leading to a significant drop in its share price by over 11% in premarket trading.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

NVDA

The AI boom has significantly benefited certain tech stocks, with NVIDIA (NASDAQ: NVDA) being a primary benefactor due to its GPUs' essential role in AI servers.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

ROKU

Roku's Q3 2024 revenue exceeded $1 billion, marking a significant milestone with a 16% YoY increase in platform services. Despite stock volatility and a cautious Q4 outlook, Roku is expanding its advertising reach and targeting international markets for growth.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

COST

Costco Wholesale Corp. (NASDAQ: COST) has reached new 52-week highs, with its stock up nearly 43% year-to-date and almost 200% over the past five years, making it a standout in the consumer defensive sector.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

ICAGY

Rolls-Royce Holdings PLC is under scrutiny due to delays in engine maintenance, leading to flight cancellations by airlines such as British Airways and Virgin Atlantic.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

CTOR

CTXR

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. announced promising preliminary results from a Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors. The study showed a 27% Objective Response Rate and a 33% Clinical Benefit Rate, with a median Progression Free Survival of 57 weeks. The regimen was well-tolerated with no serious immune-related adverse events.

Portfolio Pulse from

November 11, 2024 | 2:00 pm

STWD

Starwood Property Trust (STWD) offers a 9.9% dividend yield, supported by a diversified portfolio and a strategic shift away from office properties. Its strong financial position and expanding infrastructure investments enhance its appeal for income-focused investors. STWD's robust liquidity and discount to undepreciated book value make it a compelling high yield choice.

Portfolio Pulse from

November 11, 2024 | 1:45 pm